GT Biopharma Inc. 宣布,截至今年6月30日,公司现金余额约为510万美元。这笔资金预计将提供充足的现金流,足以支撑公司运营直至2026年第四季度。
GT Biopharma Inc. 宣布,截至今年6月30日,公司现金余额约为510万美元。这笔资金预计将提供充足的现金流,足以支撑公司运营直至2026年第四季度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.